# DESCRIPTION

## TECHNICAL FIELD

- introduce tooth agenesis treatment

## BACKGROUND ART

- describe tooth agenesis problem
- limitations of current treatments
- prior art in tooth regeneration

## SUMMARY OF INVENTION

### Problem to be Solved by Invention

- identify problem of tooth agenesis

### Solution for Problem

- propose neutralizing antibody targeting USAG-1
- describe antibody's effect on tooth regeneration
- define antibody or antigen-binding fragment
- specify antibody's binding to USAG-1
- describe antibody's neutralization of BMP signaling
- describe antibody's neutralization of WNT signaling
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- specify heavy chain variable region
- specify light chain variable region
- describe antibody's composition
- describe antibody's binding to USAG-1 and neutralization
- specify heavy chain and light chain complementarity determining regions
- specify heavy chain and light chain variable regions
- describe antibody that competes with USAG-1 binding
- specify humanized or chimeric antibody
- describe pharmaceutical composition for dental regenerative therapy
- specify antibody's use in tooth regenerative therapy
- describe clinical application of antibody treatment

### Effects of the Invention

- describe benefits of tooth regenerative therapy

## MODE FOR CARRYING OUT THE INVENTION

- introduce USAG-1
- describe USAG-1 function
- motivate tooth agenesis treatment
- describe Runx2-deficient mouse model
- describe USAG-1 gene-deficient mouse model
- describe double-knockout mouse experiment
- summarize tooth formation recovery result
- motivate inhibition of USAG-1
- describe crossing congenital tooth agenesis model mice with USAG-1 gene-deficient mouse
- describe double-knockout mice analysis
- summarize tooth formation recovery result
- describe production of human USAG-1 recombinant protein
- describe production of antibodies
- describe antibody function
- define neutralizing activity
- describe BMP signaling inhibitory activity
- describe Wnt signaling inhibitory activity
- describe antibody or antigen-binding fragment thereof
- describe sequencing and analysis of antibodies
- describe variable regions and complementarity determining regions
- describe specific antibodies (A-E)
- provide antibodies or antigen-binding fragments thereof
- define antibody A
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody A
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody A
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody A
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody A
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody A
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody A
- define antibody B
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody B
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- define antibody B
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody B
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody B
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody B
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody B
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody B
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody B
- define antibody C
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody C
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody C
- define antibody C
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody or antigen-binding fragment
- specify heavy chain variable region
- specify light chain variable region
- provide more preferred antibody or antigen-binding fragment
- specify heavy chain variable region with substitution
- specify light chain variable region with substitution
- provide still more preferred antibody or antigen-binding fragment
- specify heavy chain complementarity determining regions with sequence identity
- specify light chain complementarity determining regions with sequence identity
- provide preferred antibody or antigen-binding fragment with sequence identity
- specify heavy chain variable region with sequence identity
- specify light chain variable region with sequence identity
- provide more preferred antibody or antigen-binding fragment with sequence identity
- specify heavy chain variable region with substitution and sequence identity
- specify light chain variable region with substitution and sequence identity
- provide still more preferred antibody or antigen-binding fragment with sequence identity
- define antibody D or mutant
- specify heavy chain complementarity determining regions with sequence identity
- specify light chain complementarity determining regions with sequence identity
- provide preferred antibody or antigen-binding fragment with sequence identity
- specify heavy chain complementarity determining regions with exact sequence
- specify light chain complementarity determining regions with exact sequence
- provide more preferred antibody or antigen-binding fragment with exact sequence
- define antibody D
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody D
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody D
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody D
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody D
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody D
- specify heavy chain variable region
- specify light chain variable region
- provide preferred antibody D
- define antibody E
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody E
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide preferred antibody E
- define antibody E
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide sequence identity options
- specify heavy chain variable region
- specify light chain variable region
- provide sequence identity options
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide sequence identity options
- specify heavy chain variable region
- specify light chain variable region
- provide sequence identity options
- specify heavy chain complementarity determining regions
- specify light chain complementarity determining regions
- provide sequence identity options
- specify heavy chain variable region
- specify light chain variable region
- provide sequence identity options
- define "several"
- define "substitution"
- provide examples of conservative substitution
- specify amino acid substitution options
- conclude antibody E definition
- define sequence identity
- determine sequence identity using algorithm
- describe antibody or antigen-binding fragment
- provide antibody or antigen-binding fragment that binds to epitope
- describe competition for binding
- define competition
- describe competitive binding assay
- explain epitope binning
- describe binding affinity
- describe isolated antibody
- describe polyclonal or monoclonal antibody
- describe humanized or chimeric antibody
- describe antigen-binding fragment
- describe isolated nucleic acid
- describe pharmaceutical composition
- describe dental regeneration therapy
- describe pharmaceutical composition formulation
- describe administration route
- describe dental regenerative therapy application
- describe congenital tooth agenesis treatment
- describe acquired tooth loss treatment
- describe pharmaceutical composition administration
- describe dose determination
- describe neutralizing activity
- describe method of regenerating a tooth
- provide examples of the present invention

### Example 1

- prepare antibody 1
- confirm Wnt inhibitory activity
- confirm BMP inhibitory activity
- establish USAG-1KO mice
- prepare neutralizing antibodies
- perform primary screening
- select positive clones
- measure antibody subclasses
- confirm neutralizing activity
- classify antibodies by neutralizing activity
- obtain 5 kinds of mouse anti-USAG-1 neutralizing antibodies

### Example 2

- express and purify PA-mUSAG-1 protein
- confirm WNT and BMP signaling inhibitory activity
- confirm neutralizing activity of 5 mouse anti-USAG-1 neutralizing antibodies

### Example 3

- administer antibody A to congenital tooth agenesis model mice

### Example 4

- administer antibody B to congenital tooth agenesis model mice
- observe formation of supernumerary teeth

### Example 5

- administer mixture of 5 antibodies to Wnt10a-deficient mice

### Example 6

- perform binding assay using mouse/human N-terminal PA-tagged USAG-1 proteins
- confirm recognition of human USAG-1 protein by 5 mouse anti-USAG-1 neutralizing antibodies
- perform immunostaining using 5 mouse anti-USAG-1 neutralizing antibodies

### Example 7

- prepare mouse USAG-1 neutralizing antibodies using rat USAG-1 protein
- perform primary screening by ELISA
- select positive clones
- measure antibody subclasses
- confirm neutralizing activity
- obtain 4 types of mouse anti-USAG-1 neutralizing antibodies

### Example 8

- perform epitope binning using Octet Red
- group antibodies based on epitopes
- classify 9 antibodies into 4 groups
- analyze competition between antibodies

### Example 9

- epitope mapping of antibody E37
- prepare peptide library
- bind peptides to cellulose membrane
- add E37 antibody as primary antibody
- incubate and wash
- add HRP-conjugated anti-mouse antibody
- use ECL solution for color development
- identify epitope sequence
- summarize epitope mapping results
- introduce Example 10
- determine affinities of antibodies
- use Octet-based BLI method
- immobilize antibodies on biosensor
- add purified recombinant mouse USAG-1 protein
- obtain binding and dissociation curves
- calculate affinities by global fitting
- show results in Table 2
- introduce Example 11
- determine neutralizing activities of antibody B14
- use WNT reporter assay
- use BMP ALP assay
- show results in FIG. 17
- calculate EC50 values
- introduce Example 12
- administer antibodies to mice
- evaluate tooth formation
- show results in Table 3

## INDUSTRIAL APPLICABILITY

- application of antibody

